Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)

Trial Profile

A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 11 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD 4547 (Primary) ; Durvalumab (Primary) ; Erlotinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Palbociclib (Primary) ; Rilotumumab (Primary) ; Talazoparib (Primary) ; Taselisib (Primary) ; Tremelimumab (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms Lung-MAP
  • Most Recent Events

    • 06 Sep 2019 Status changed from recruiting to active, no longer recruiting.
    • 11 Jul 2019 Results assessing response rate to palbociclib in patients with cell cycle gene abnormalities published in the Journal of Thoracic Oncology
    • 04 Jun 2019 Results analysing clinical efficacy of talazoparib, in advanced stage squamous cell lung cancer harboring HRRD mutation presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top